Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine February 2020, 61 (2) 6A;
  • Article
  • Info & Metrics
  • PDF
Loading

FAP nuclear theranostics: Calais looks at the current state of scientific and industry interest in advancing imaging and therapy with fibroblast activation proteins targeting cancer-associated fibroblasts, a major constituent of tumor stroma.

Page 163

Spatial-temporal ordering of amyloid: Fantoni and colleagues summarize current research in detection of regional amyloid deposition patterns and the potential for staging amyloid pathology, including expanding applications of PET imaging.

Page 166

Steroid hormone receptor imaging: Kumar and colleagues highlight recent achievements in preclinical and clinical imaging of estrogen and progesterone receptors in breast cancer.

Page 172

Mutation patterns in radioiodine refractoriness: Liu and colleagues investigate the role of BRAF V600E and TERT promoter mutations, particularly in tandem, in loss of radioactive iodine avidity in recurrent papillary thyroid cancer.

Page 177

18F-DCFPyL versus Na18F: Rowe and colleagues undertake a head-to-head comparison of prostate-specific membrane antigen–targeted 18F-DCFPyL PET and Na18F PET to determine which is more sensitive for detection of lesions suggestive of bone metastases in prostate cancer.

Page 183

Reducing 68Ga PET/CT dose? Rauscher and colleagues explore the definition of a clinically useful lower limit of injected dose for 68Ga–prostate-specific membrane antigen–11 PET/CT imaging of prostate cancer.

Page 189

68Ga-PSMA-11 PET/MRI: Kranzbühler and colleagues focus on patients with biochemical recurrence of prostate cancer and prostate-specific antigen values ≤0.5 ng/mL to assess the detection rate for 68Ga-PSMA-11 PET/MRI.

Page 194

18F-JK-PSMA-7 PET/CT: Dietlein and colleagues assess the clinical utility of 18F-JK–prostate-specific membrane antigen–7 for PET/CT imaging of patients with prostate cancer and compare findings with those from 68Ga-PSMA-11 imaging.

Page 202

Advanced reconstruction for PSMA PET: Jansen and colleagues explore the impact of advanced PET image reconstruction methods on biochemically recurrent prostate cancer localization and interobserver agreement with 18F-DCFPyL PET/CT scans in patients with low prostate-specific antigen values.

Page 210

Tumor-to-blood ratio in NETs: Ilan and colleagues evaluate the tumor-to-blood ratio as an alternative tool for semiquantitative assessment of 68Ga-DOTATOC and 68Ga-DOTATATE tumor uptake and for therapy monitoring in patients with neuroendocrine tumors.

Page 217

177Lu-DOTATATE in NETS: Hope and members of the North American Neuroendocrine Tumor Society and SNMMI present a consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy in neuroendocrine tumors.

Page 222

Metal-ion labeled DOTATATE imaging: Andersen and colleagues compare 68Ga-DOTATATE, 64Cu-DOTATATE, and 55Co-DOTATATE PET/CT in mice to determine whether the 55Co label conveys advantages for imaging at delayed time points.

Page 228

Cyanine-spacer–based PSMA hybrid tracers: Hensbergen and colleagues describe development of a 99mTc-labeled prostate-specific membrane antigen–targeted tracer incorporating a fluorescent dye for radioguided surgery.

Page 234

TRT radiopharmaceuticals for mGluR1: Xie and colleagues describe 2 new radiopharmaceuticals, 131I-IITM and 211At-AITM, targeting the ectopic metabotropic glutamate receptor 1 in melanomas for radionuclide therapy studies.

Page 242

PET after cardiac transplantation: Miller and colleagues compare the diagnostic and prognostic utility of stress myocardial blood flow and myocardial flow reserve quantitation by PET in cardiac allograft vasculopathy after cardiac transplantation.

Page 249

Recovered mGluR5 in alcohol dependence: Ceccarini and colleagues research whether decreased cerebral metabotropic glutamate receptor 5 availability in alcohol-dependent patients normalizes during abstinence and whether initial 18F-FPEB mGluR5 imaging parameters can predict individual relapse.

Page 256

Tau PET in syntactic network disease: Pascual and colleagues study tau propagation patterns in the left hemispheric syntactic network in patients with nonfluent primary progressive aphasia.

Page 263

68Ga-RGD PET/CT and angiogenesis: Lobeek and colleagues detail the results of a clinical feasibility study designed to demonstrate that 68Ga-labeled arginine-glycine-aspartate tripeptide sequence PET/CT can be used to quantitatively assess angiogenesis in peripheral arteriovenous malformations.

Page 270

18F-FDG PET/MRI and CMRGlc mapping: Shiyam Sundar and colleagues describe a fully automated processing pipeline to support noninvasive absolute quantification of the cerebral metabolic rate for glucose in a clinical setting.

Page 276

Total-body parametric PET/CT imaging: Zhang and colleagues demonstrate the capability of total-body parametric imaging and quantify improvements in image quality and kinetic parameter estimation by direct and kernel reconstruction of uEXPLORER data.

Page 285

High-throughput small-animal PET/CT: Greenwood and colleagues report on development of a device to simultaneously image up to 4 mice, thereby reducing costs and maximizing radiotracer efficiency when compared with scans performed on a single mouse bed.

Page 292

Denoising nuclear medicine images: Minarik and colleagues investigate whether noise can be removed in whole-body bone scans using convolutional neural networks trained with sets of noisy and noiseless images obtained by Monte Carlo simulation.

Page 298

  • © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (2)
Journal of Nuclear Medicine
Vol. 61, Issue 2
February 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Feb 2020, 61 (2) 6A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Feb 2020, 61 (2) 6A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE
  • Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE
  • Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye–Protein Interaction
  • High-Throughput PET/CT Imaging Using a Multiple-Mouse Imaging System
  • An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application
  • Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer
  • Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer
  • Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?
  • Promise of Fully Integrated PET/MRI: Noninvasive Clinical Quantification of Cerebral Glucose Metabolism
  • The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging
  • Multimodal 18F-AV-1451 and MRI Findings in Nonfluent Variant of Primary Progressive Aphasia: Possible Insights on Nodal Propagation of Tau Protein Across the Syntactic Network
  • A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using 68Ga-RGD PET/CT
  • FAP: The Next Billion Dollar Nuclear Theranostics Target?
  • Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients
  • Comparative Prognostic and Diagnostic Value of Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation
  • Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL
  • NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
  • Denoising of Scintillation Camera Images Using a Deep Convolutional Neural Network: A Monte Carlo Simulation Approach
  • Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER
  • 131I-IITM and 211At-AITM: Two Novel Small-Molecule Radiopharmaceuticals Targeting Oncoprotein Metabotropic Glutamate Receptor 1
  • The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
  • Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire